Fly News Breaks for February 20, 2020
Feb 20, 2020 | 07:54 EDT
SunTrust analyst David MacDonald raised his price target on Amedisys to $225 and kept his Buy rating after its Q4 earnings beat and FY20 guidance. The analyst says the quarter was highlighted by the company's solid organic trends, robust cash flow, and margin expansion, adding that its industry drivers are "meaningful" and its strategic position remains "enviable".
News For AMED From the Last 2 Days
There are no results for your query AMED